Novo Nordisk said the side effects in trials so far for its experimental obesity drug CagriSema were similar to its GLP-1 ...

CRB-913 brain levels are 15-fold lower than monlunabant in lean miceDose-response demonstrated for a range of 5 to 80 mg/kg/day achieving up to ...

Bagsværd, 6 November 2024 - Financial report for the period 1 January 2024 to 30 September 2024 Operating profit increased by ...

Viking Therapeutics' weight loss drug VK2735 may challenge Novo Nordisk and Eli Lilly's dominance in the obesity drug space ...

Welcome to the third-quarter 2024 Novo Nordisk A/S earnings conference call. [Operator instructions] Please be advised that ...

CRB-913 brain levels (both C max and AUC) were 15-fold lower than monlunabant at the same dose in mice. Plasma-to-brain ratio for CRB-913 was 10 times higher than monlunabant and 50 times higher ...

Monlunabant was evaluated in a phase 2a trial (ClinicalTrials.gov Identifier: NCT05891834) in patients with obesity and metabolic syndrome (N=243). Results showed patients treated with monlunabant ...

The prevalence of obesity continues to remain high in the US, making the demand for effective treatments even more urgent.

Key findings: CRB-913 brain levels were 15-fold lower than monlunabant at the same dose in mice. Plasma-to-brain ratio for CRB-913 was 10 times higher than monlunabant and 50 times higher than ...

Q3 2024 Earnings Call Transcript November 7, 2024 Skye Bioscience, Inc. beats earnings expectations. Reported EPS is $-0.1, expectations were $-0.25. Operator: Ladies and gentlemen, thank you for ...